A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT01026142
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 452
- Adult female patients >/=18 years of age
- Metastatic HER2 positive breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Disease progression during or following trastuzumab-based therapy for 1st line metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)
- Prior treatment with taxane-containing regimen
- Left ventricular ejection fraction (LVEF) >/=50 percent
- For women of childbearing potential agreement to use highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment
- Prior treatment with pertuzumab or capecitabine
- Concurrent treatment with other experimental drug
- Concurrent immunotherapy or anticancer hormonal therapy
- Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)
- Central nervous system (CNS) metastases, which are not well controlled
- History of exposure to anthracycline cumulative dose equivalent to 360mg/m2
- History of congestive heart failure of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment
- History of myocardial infarction within 6 months prior to randomization
- History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab
- History of another cancer which could affect compliance or result interpretation
- Inadequate organ function
- Pregnant or breastfeeding women
- life expectancy < 12 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description B: Capecitabine + Trastuzumab + Pertuzumab Capecitabine - B: Capecitabine + Trastuzumab + Pertuzumab Pertuzumab - A: Capecitabine + Trastuzumab Capecitabine - A: Capecitabine + Trastuzumab Trastuzumab - B: Capecitabine + Trastuzumab + Pertuzumab Trastuzumab -
- Primary Outcome Measures
Name Time Method Progression Free Survival (Independent Assessment) Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years). Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) From randomization until death from any cause (up to 7.5 years). Overall Survival (OS) was defined as the time from the date of randomization to the date of death from any cause. The results of the final OS analysis are presented here. Participants who were alive or lost to follow-up at the time of the analysis were censored at the last known alive date. Participants with no postbaseline information were censored at the time of randomization plus 1 day. Prior to the final data analysis cut-off, it was ensured that all participants who were in survival follow-up had been contacted as recently as possible within the last 3 months to confirm current survival status.
Overall Survival (OS) Rate Based on a 2-year Truncated Analysis From randomization until death from any cause (up to 2 years) The Overall Survival (OS) 2-year truncated analysis is the Kaplan-Meier estimate of the percentage of participants who were surviving at 2 years. OS is defined as the time from the date of randomization to the date of death from any cause, with censoring of all events and follow-up beyond the end of the second year.
Investigator Assessment Progression-Free Survival (PFS) Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 7.5 years). Investigator Assessment Progression-Free Survival (PFS) was defined as the time from randomization to the first documented progressive disease, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, or death from any cause, whichever occurred first. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years). Time to Progression (TTP) was defined as time between randomization and the first occurrence of progressive disease (PD), based on IRF assessment.
Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years). Time to Treatment Failure (TTF) was defined as time between randomization and date of disease progression based on independent review, death, or withdrawal of treatment due to adverse events, withdrawn informed consent, refusal of treatment/failure to cooperate, or failure to return, whichever occurred first.
Overall Objective Response Rate (ORR) Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years). Overall Objective Response Rate is based upon investigator and IRF assessments. Objective Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among those who had measurable disease at baseline. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Clinical Benefit Rate (CBR) Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years). Clinical Benefit Rate is based upon Independent Review Facility (IRF) assessments; defined as the percentage of participants a complete response (CR), partial response (PR), or stable disease for at least 8 cycles or 6 months.
Duration of Objective Response Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years). Duration of Objective Response was defined for the subpopulation of responders as time from first Independent Review Facility (IRF)-assessed complete response (CR) or partial response (PR) to subsequent first documented, IRF-confirmed evidence of disease progression. Only participants with an objective response were included in the analysis of duration of objective response.
Trial Locations
- Locations (190)
UZ Brussel
🇧🇪Brussel, Belgium
Queen Mary Hospital; Surgery
🇭🇰Hong Kong, Hong Kong
Semashko Central Clinical Hospital; Dept of Chemotherapy
🇷🇺Moscow, Russian Federation
Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica
🇵🇪Piura, Peru
Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny
🇵🇱Brzozów, Poland
SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary
🇷🇺Stavropol, Russian Federation
Blokhin Cancer Research Center; Combined Treatment
🇷🇺Moscow, Russian Federation
Saint-Petersburg City Clinical Oncology Dispensary
🇷🇺St Petersburg, Russian Federation
Phramongkutklao Hospital;Dept Surgery/Surgical Oncology Unit
🇹🇭Bangkok, Thailand
Wojewodzki Sziptal Specjalistyczny Im. Janusza Korczaka; Oddzial Onkologiczny, Oddzial Chemioterapii
🇵🇱Slupsk, Poland
Cluj Clinical County Hospital; Oncology Dept
🇷🇴Cluj-Napoca, Romania
Broomfield Hospital
🇬🇧Chelmsford, United Kingdom
Hospital Universitario de Canarias;servicio de Oncologia
🇪🇸La Laguna, Tenerife, Spain
Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department
🇷🇴Bucuresti, Romania
Regional Oncology Hospital of Krasnodar; Oncology
🇷🇺Krasnodar, Russian Federation
Consorci Hospitalari de Terrassa
🇪🇸Terrassa, Barcelona, Spain
Hospital Provincial de Castellón
🇪🇸Castellon, Spain
Hospital Ruber Internacional;Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Clinic i Provincial; Servicio de Farmacia
🇪🇸Barcelona, Spain
Euroclinic Center of Oncology SRL
🇷🇴Iasi, Romania
Fundacion Hospital de Alcorcon; Servicio de Oncologia
🇪🇸Alcorcon, Madrid, Spain
Hospital de Basurto; Servicio de Oncologia
🇪🇸Bilbao, Vizcaya, Spain
Hospital La Paz
🇪🇸Madrid, Spain
Royal Cornwall Hospital; Dept of Clinical Oncology
🇬🇧Truro, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Hospital de Sagunto; Servicio de Oncologia
🇪🇸Sagunto, Valencia, Spain
Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia
🇪🇸Santa Cruz de Tenerife, Tenerife, Spain
Institut Catala d Oncologia Hospital Duran i Reynals
🇪🇸Barcelona, Spain
Complejo Asistencial Universitario de Leon; Servicio de Oncologia
🇪🇸Leon, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Complejo Hospitalario de Pontevedra; Servicio de Oncologia
🇪🇸Pontevedra, Spain
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Hospital Univ. Nuestra Señora de Valme;
🇪🇸Sevilla, Spain
Hospital Sant Pau i Santa Tecla
🇪🇸Tarragona, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Tuen Mun Hospital; Clinical Oncology
🇭🇰Hong Kong, Hong Kong
Hospital of Aladar Petz; Dept of Oncoradiology
🇭🇺Gyor, Hungary
Centre Antoine Lacassagne; Hopital De Jour A2
🇫🇷Nice, France
Fundación Investigar
🇦🇷Buenos Aires, Argentina
Instituto FIDES
🇦🇷La Plata, Argentina
Hospital Britanico; Oncologia
🇦🇷Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Quilmes
🇦🇷Quilmes, Argentina
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
🇦🇹Salzburg, Austria
A.Ö. Landesschwerpunktkrankenhaus Krems; Abtl. F. Innere Med.
🇦🇹Krems, Austria
ISIS Clinica Especializada
🇦🇷Santa Fe, Argentina
Landeskrankenhaus Rankweil; Interne E
🇦🇹Rankweil, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
🇦🇹Wien, Austria
Imeldaziekenhuis
🇧🇪Bonheiden, Belgium
AZ KLINA
🇧🇪Brasschaat, Belgium
GHdC Site Notre Dame
🇧🇪Charleroi, Belgium
CH Jolimont - Lobbes (Jolimont)
🇧🇪Haine-Saint-Paul, Belgium
Hospital Sao Lucas - PUCRS
🇧🇷Porto Alegre, RS, Brazil
CHU Sart-Tilman
🇧🇪Liège, Belgium
Clinique Ste-Elisabeth
🇧🇪Namur, Belgium
Oncologia Sul Capixaba Servicos Medicos - Oncosul
🇧🇷Cachoeiro Do Itapemirim, ES, Brazil
Hospital Perola Byington
🇧🇷Sao Paulo, SP, Brazil
AZ Nikolaas (Lodewijk)
🇧🇪Sint-Niklaas, Belgium
Hospital A. C. Camargo; Oncologia
🇧🇷Sao Paulo, SP, Brazil
Humber River Hospital
🇨🇦Toronto, Ontario, Canada
Centro Oncológico de Mogi das Cruzes
🇧🇷São Paulo- SP, SP, Brazil
Durham Regional Cancer Centre
🇨🇦Oshawa, Ontario, Canada
Masarykuv onkologicky ustav; Oncology II
🇨🇿Brno, Czechia
Uni Hospital For Tumours; Dept of Medical Oncology
🇭🇷Zagreb, Croatia
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
🇨🇦Toronto, Ontario, Canada
University Hospital; Oncology and Radiotherapy
🇨🇿Hradec Kralove, Czechia
Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
🇨🇿Praha 2, Czechia
Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie
🇨🇿Praha, Czechia
Tartu University Hospital; Clinic of Hematology and Oncology
🇪🇪Tartu, Estonia
C.H. Du Pays D'aix En Provence Service du Dr Blanc
🇫🇷Aix En Provence, France
North Estonia Medical Centre Foundation; Oncology Centre
🇪🇪Tallinn, Estonia
Centre Oncologie Du Pays Basque
🇫🇷Bayonne, France
Centre Hospitalier Fleyriat; Oncologie/Hematologie
🇫🇷Bourg En Bresse, France
Centre Georges Francois Leclerc; Oncologie 3
🇫🇷Dijon, France
Centre Leon Berard; Oncologie Genetique
🇫🇷Lyon, France
CHU Henri Mondor; Service d'Oncologie Medicale
🇫🇷Creteil, France
Institut Curie; Oncologie Medicale
🇫🇷Paris, France
Hopital Saint Antoine; Sce Oncologie
🇫🇷Paris, France
Institut Jean Godinot; Oncologie Medicale
🇫🇷Reims CEDEX, France
Centre Henri Becquerel; Oncologie Medicale
🇫🇷Rouen, France
Centre Rene Huguenin; CONSULT SPECIALISEES
🇫🇷St Cloud, France
Hopital Hautepierre; Hematologie Oncologie
🇫🇷Strasbourg, France
Institut Claudius Regaud; Departement Oncologie Medicale
🇫🇷Toulouse, France
CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie
🇩🇪Berlin, Germany
Klinikum Bremen-Mitte gGmbH; Frauenklinik
🇩🇪Bremen, Germany
Clinique Pasteur; Oncologie Medicale
🇫🇷Toulouse, France
Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
🇩🇪Darmstadt, Germany
Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
🇩🇪Essen, Germany
Klinikum Dortmund gGmbH Klinikzentrum Mitte
🇩🇪Dortmund, Germany
Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe
🇩🇪Frankfurt, Germany
Universitätsklinikum Hamburg-Eppendorf; Zentrum für operative Medizin Klinik für Gynäkologie
🇩🇪Hamburg, Germany
Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
🇩🇪Fulda, Germany
Diakovere Henriettenstift, Frauenklinik
🇩🇪Hannover, Germany
HOPA MVZ GmbH
🇩🇪Hamburg, Germany
Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
🇩🇪Hannover, Germany
ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik
🇩🇪Karlsruhe, Germany
St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe
🇩🇪Koeln, Germany
Systemedic Frauenarzte Pruener Gang
🇩🇪Kiel, Germany
Institut für Versorgungsforschung in der Onkologie GbR Koblenz
🇩🇪Koblenz, Germany
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Lübeck, Germany
St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz
🇩🇪Mainz, Germany
Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik
🇩🇪München, Germany
Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Münster, Germany
St. Josefs Klinik; Medizinische Klinik
🇩🇪Offenburg, Germany
Johanniter Klinik
🇩🇪Stendal, Germany
GRN Klinik Weinheim
🇩🇪Weinheim, Germany
Fövárosi Önkormányzat Bajcsy-Zsilinszky Kórház; Onkológiai Osztály
🇭🇺Budapest, Hungary
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
🇭🇺Budapest, Hungary
Semmelweis Egyetem Onkologiai Központ
🇭🇺Budapest, Hungary
Ogyi, Orszagos Gyogyszereszeti Intezet
🇭🇺Budapest, Hungary
Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
🇭🇺Budapest, Hungary
Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek
🇭🇺Gyula, Hungary
Municipal Hospital of Uzsoki Utca; Centre of Oncoradiology
🇭🇺Budapest, Hungary
Kaposi Mor County Hospital; Dept. of Oncology
🇭🇺Kaposvar, Hungary
Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly
🇭🇺Miskolc, Hungary
Josa Andras Korhaz; Dept of Oncoradiology
🇭🇺Nyíregyháza, Hungary
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
🇭🇺Szeged, Hungary
Pécsi Tudományegyetem Áok; Onkoterapias Intezet
🇭🇺Pecs, Hungary
Fejér Megyei Szent György Kórház; Onkológiai Osztály
🇭🇺Szekesfehervar, Hungary
Istituto Tumori Fondazione Pascale; Endocrinologia Oncologica
🇮🇹Napoli, Campania, Italy
Ospedale Cervesi di Cattolica ; Unità Operativa di Oncologia ed Oncoematologia
🇮🇹Cattalica, Emilia-Romagna, Italy
Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli
🇮🇹Bologna, Emilia-Romagna, Italy
AUSL Cesena; Servizio di Oncologia
🇮🇹Cesena, Emilia-Romagna, Italy
Ausl Ravenna-Osp.Infermi; Day Hospital Oncologia Medica
🇮🇹Faenza, Emilia-Romagna, Italy
Ospedale Umberto I ASL di Ravenna Presidio Ospedaliero di Lugo
🇮🇹Lugo, Emilia-Romagna, Italy
Azienda USL di Ravenna; Unità Operativa di Oncologia Medica
🇮🇹Ravenna, Emilia-Romagna, Italy
Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia
🇮🇹Rimini, Emilia-Romagna, Italy
ASST DI CREMONA; Dipartimento Aziendale Oncologico
🇮🇹Cremona, Lombardia, Italy
Istituto Regina Elena; Oncologia Medica A
🇮🇹Roma, Lazio, Italy
Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna
🇮🇹Roma, Lazio, Italy
Ospedale Mater Salutis; Dept of Oncology
🇮🇹Legnago, Lombardia, Italy
ASST LARIANA; Oncologia
🇮🇹S. Fermo Della Battaglia (CO), Lombardia, Italy
Asst Papa Giovanni XXIII; Oncologia Medica
🇮🇹Bergamo, Lombardia, Italy
ASST DI MONZA; Oncologia Medica
🇮🇹Monza, Lombardia, Italy
Instituto de Oncología de Rosario
🇦🇷Rosario, Argentina
IRCCS Fondazione Maugeri; Oncologia Medica II
🇮🇹Pavia, Lombardia, Italy
Ospedale Civile; Oncologia Medica
🇮🇹Sassari, Sardegna, Italy
A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica
🇮🇹Torino, Piemonte, Italy
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Azienda ospedaliero-universitaria careggi, Sezione di radioterapia del dipartimento di fisiopatolo
🇮🇹Firenze, Toscana, Italy
ARNAS-Ospedale Civico Maurizio Ascoli; Unità Operativa di Oncologia Medica
🇮🇹Palermo, Sicilia, Italy
A.O. Universitaria Pisana; Oncologia
🇮🇹Pisa, Toscana, Italy
Seoul National University Hosp; Dept Internal Med Hem Onc
🇰🇷Seoul, Korea, Republic of
Klinikum Sindelfinden Boblingen
🇩🇪Böblingen, Germany
Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
🇰🇷Seoul, Korea, Republic of
Oaxaca Site Management Organization
🇲🇽Oaxaca, Mexico
Korea University Guro Hospital; Oncology
🇰🇷Seoul, Korea, Republic of
Praxis für Onkologie und Hämatologie
🇩🇪Recklinghausen, Germany
Hospital Juan Ramon Jimenez;Servicio de Oncologia
🇪🇸Huelva, Spain
Vu Medisch Centrum; Afdeling Maag-, Darm- En Leverziekte
🇳🇱Amsterdam, Netherlands
Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology
🇵🇪Arequipa, Peru
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
🇩🇪Trier, Germany
S.-Peterburg Pavlov State Medical University ; Haematology
🇷🇺St Petersburg, Russian Federation
Hospital Universitario Puerta de Hierro
🇪🇸Majadahonda, Madrid, Spain
Fundacion Jimenez Diaz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Virgen Macarena; Servicio de Oncologia
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Salamanca; Servicio de Oncologia
🇪🇸Salamanca, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
🇪🇸Toledo, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Hospital Universitario la Fe; Servicio de Oncologia
🇪🇸Valencia, Spain
Ramathibodi Hospital; Department of Surgery/Breast and Endocrine Unit
🇹🇭Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial
🇹🇭Chiang Mai, Thailand
Srinagarind Hospital; Department of Surgery
🇹🇭Khon Kaen, Thailand
Songklanagarind Hospital; Department of Surgery
🇹🇭Songkla, Thailand
Royal Bournemouth General Hospital; Oncology
🇬🇧Bournemouth, United Kingdom
Velindre Cancer Centre; Oncology Dept
🇬🇧Cardiff, United Kingdom
University Hospital of North Durham; Oncology
🇬🇧Durham, United Kingdom
Christie Hospital; Breast Cancer Research Office
🇬🇧Manchester, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
Peterborough City Hospital, Edith Cavell Campus; Oncology Department
🇬🇧Peterborough, United Kingdom
Great Western Hospital; Clinical Oncology
🇬🇧Swindon, United Kingdom
Hospital Nacional Edgardo Rebagliati Martins
🇵🇪Jesus Maria, Peru
Clinica Anglo Americana - Centro de Investigacion Oncologia CAA
🇵🇪Lima, Peru
Wojewodzki Szpital Zespolony; Oddzial Chemioterapii
🇵🇱Elblag, Poland
Wojewodzkie Centrum Onkologii
🇵🇱Gdansk, Poland
Spitalul Clinic Sf. Maria; Departmental De Oncologie
🇷🇴Bucharest, Romania
Institute Of Oncology Bucharest; Medical Oncology
🇷🇴Bucharest, Romania
Prof. Dr. I. Chiricuta Institute of Oncology
🇷🇴Cluj Napoca, Romania
GUZ Perm Region Oncology Dispensary
🇷🇺Perm, Russian Federation
Hospital Clinica Benidorm
🇪🇸Benidorm, Alicante, Spain
Medisprof SRL
🇷🇴Cluj-Napoca, Romania
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
🇭🇺Szolnok, Hungary
AZ Groeninge
🇧🇪Kortrijk, Belgium
Clinique Saint-Joseph
🇧🇪Liège, Belgium
COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
🇵🇱Lublin, Poland
Municipal Clinical Hospital Filantropia; Oncology
🇷🇴Craiova, Romania
Centro Oncológico Estatal; ISSSEMYM Oncología
🇲🇽Toluca, Mexico
Complejo Hospitalario Torrecardenas; Servicio de Oncologia
🇪🇸Almería, Almeria, Spain
Queen Elizabeth Hospital; Clinical Oncology
🇭🇰Hong Kong, Hong Kong